A 99mTc-tricine-HYNIC-labeled Peptide Targeting the Melanocortin-1 Receptor for Melanoma Imaging

Authors

  • Babak Fallahi Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • Danial Shamshirian Department of Radiopharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  • Davood Beiki Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • Maliheh Hajiramazanali Department of Radiopharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Mostafa Erfani Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Abstract:

Melanocortin-1 (MC1) receptor is an attractive melanoma-specific target for the development of α-MSH peptide based imaging and therapeutic agents. In this work a new lactam bridge α-MSH analogue was synthesized and radiolabeled with 99mTc via HYNIC chelator and tricine as co-ligand. Also, stability in human serum, receptor bound internalization and tissue biodistribution in tumor bearing nude mice were thoroughly investigated. Radiolabeling with 99mTc was performed at high specific activities (163MBq/nmol) with an acceptable labeling yield (>98%). The radioligand showed specific internalization into B16/F10 cells (13.35 ± 0.9% at 4 hours). In biodistribution studies, a receptor-specific uptake was observed in MC1 receptor positive organ so that after 4 hours the tumor uptake was 4.51±0.11 % ID/g. Predominant renal excretion pathway with a highest accumulation of activity in tumor was observed for this radiopeptide. Obtained results show that the new designed labeled peptide conjugate can be a suitable candidate for diagnosis of metastatic melanomas.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

a 99mtc-tricine-hynic-labeled peptide targeting the melanocortin-1 receptor for melanoma imaging

melanocortin-1 (mc1) receptor is an attractive melanoma-specific target for the development of α-msh peptide based imaging and therapeutic agents. in this work a new lactam bridge α-msh analogue was synthesized and radiolabeled with 99mtc via hynic chelator and tricine as co-ligand. also, stability in human serum, receptor bound internalization and tissue biodistribution in tumor bearing nude m...

full text

Synthesis, labeling, formulation and quality control of 99mTc-Tricine-HYNIC-Tyr³-Octreotide, a peptide radiopharmaceutical for imaging Somatostatin receptor positive tumors [Persian]

Somatostatin analoges labeled with different radionuclides are able used for imaging and treatment of somatostatin receptor positive tumors. In this study Tyr³-Octreotide protected at lysine as an analoge of somatostatin was conjugated with bifunctional chelating agent 6-BOC-hydrazinopyridine-3-carboxylic acid (BOC-HYNIC) and after deprotecting of conjugate, purification was performed wit...

full text

evaluation and comparison of different quality control methods in radiochemical purity determination of new peptide kits 99mtc-edda-tricine-hynic-tyr3-octreotide and 99mtc-edda-tricine-hynic-tyr3-octreotate for imaging somatostatin receptor positive tumors [persian]

introduction: using labeled peptides enjoys high importance in nuclear medicine. somatostatin analogs labeled with different radionuclide are vastly investigated for diagnosis or treatment of somatostatin receptor positive tumors. labeling somatostatin analogs with 99mtc as alternative of 111in needs doing different quality control method for determination of labeling yield and complex stabilit...

full text

synthesis, labeling, formulation and quality control of 99mtc-tricine-hynic-tyr³-octreotide, a peptide radiopharmaceutical for imaging somatostatin receptor positive tumors [persian]

somatostatin analoges labeled with different radionuclides are able used for imaging and treatment of somatostatin receptor positive tumors. in this study tyr³-octreotide protected at lysine as an analoge of somatostatin was conjugated with bifunctional chelating agent 6-boc-hydrazinopyridine-3-carboxylic acid (boc-hynic) and after deprotecting of conjugate, purification was performed with prep...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 15  issue 3

pages  349- 360

publication date 2016-10-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023